

Figure S1 Progression-free survival of patients with advanced non-squamous NSCLC treated with the association of pembrolizumab plus chemotherapy, according to the number of metastatic site. NSCLC, non-small cell lung cancer.




Figure S2 Progression-free survival of patients with advanced non-squamous NSCLC treated with the association of pembrolizumab plus chemotherapy and considered as “challenging subgroups” (A: presence of liver metastases; B: presence of brain metastases). NSCLC, non-small cell lung cancer.

Table S1 Time and courses of the combination treatment

	N=121
No of carboplatin cures	3.6
No of pemetrexed cures	6.7
No of pembrolizumab cures	10.8
Median duration of treatment with pemetrexed (weeks)	19.4
Median duration of treatment with carboplatin (weeks)	10.3
Median duration of treatment with pembrolizumab (weeks)	22.0